It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
Although the number of patients suffering from heart failure with preserved ejection fraction (HFpEF) increases, the routine diagnosis remains a challenge. In the absence of a pathognomonic sign for HFpEF or specific treatment strategies, a prognosis‐based characterization of suspected patients remains promising for both the risk stratification of the patients and a disease definition. The Heart Failure Association (HFA) of the European Society of Cardiology has introduced an algorithm with different levels of likelihood regarding the diagnosis of HFpEF, the HFA‐PEFF score. We aimed to evaluate the predictive value of this algorithm in a large cohort regarding mortality, symptom burden, and the functional status.
Methods and results
DIAST‐CHF is a multicentre, population‐based, prospective, observational study in subjects with at least one risk factor for HFpEF between the age of 50 and 85. We calculated the HFA‐PEFF score (n = 1668) and analysed the risk groups for overall mortality, cardiovascular hospitalization, and submaximal functional capacity (6‐min walk distance) at baseline and after a follow‐up period of 10 years. Patients with high HFA‐PEFF score values 5&6 showed a higher mortality than those with an intermediate score (score values 2–4) and low score values (high 21.3% vs. intermediate 10.1% vs. low 4.3%, P < 0.001). Also, the burden of MACE (death, cardiovascular hospitalization, new myocardial infarction, first diagnosis of HF) was increased in the high score values group (high 40.7% vs. intermediate 25.9% vs. low 13.9%, P < 0.001). Similarly, patients with higher scores had higher cumulative incidences of cardiovascular hospitalizations (P = 0.011). Subjects with higher scores also had lower 6‐min walk distance both at baseline and during follow‐up.
Conclusions
The HFA‐PEFF score provides a reliable instrument to stratify suspected HFpEF patients by their risk for mortality, symptom burden, and functional status in cohort at risk with a follow‐up period of 10 years. As high HFA‐PEFF scores are associated with worse outcome, the HFA‐PEFF algorithm describes a defining approach towards HFpEF.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Mende, Meinhard 2 ; Trippel, Tobias D. 3 ; Petutschnigg, Johannes 3 ; Hasenfuss, Gerd 4 ; Nolte, Kathleen 4 ; Herrmann‐Lingen, Christoph 5 ; Feuerstein, Anna 3 ; Langhammer, Romy 6 ; Tschöpe, Carsten 7 ; Pieske, Burkert 1 ; Wachter, Rolf 8 ; Edelmann, Frank 3 1 Department of Internal Medicine and Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Department of Internal Medicine and Cardiology, German Heart Institute Berlin (DHZB), Berlin, Germany, DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
2 Clinical Trial Centre and Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany
3 Department of Internal Medicine and Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
4 DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Berlin, Germany, Department of Cardiology and Pneumology, Georg‐August University, Göttingen, Germany
5 DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Berlin, Germany, Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany
6 Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany
7 Department of Internal Medicine and Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, Berlin Institute of Health (BIH) & Berlin‐Brandenburg Center for Regenerative Therapies (BCRT), Charité ‐ Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
8 DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Berlin, Germany, Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany





